Synaptogenix Inc (SNPX)

[SF Wolf]

NTRP, in my opinion, has a favorable risk reward ratio:

Dr. Alkon, his former team at the Blanchette Rockefeller Neurosciences Institute, and other researchers in the field have identified the detailed chemical pathways and brain chemistry that they believe describes Bryostatin’s effectiveness.

Bryostatin has shown efficacy in animal studies, in a very limited number of compassionate use patients, and in a short time frame will release the results of their Phase 2 double blinded study. Safety data from previous unsuccessful cancer studies on over 1500 patients shows Bryostatin to be well tolerated. Bryostatin was recently synthesized by a research team at Stanford and licensed by Neurotrope. Financially, NTRP is well positioned, and with the exercise of outstanding warrants will raise another $50 million. NASDAQ up-listing is around the corner.

Also consider that the Trump administration has indicated it wants less oversight and more fast track approval of promising drugs and it just might turn out that with positive Phase 2b results Bryostatin will be an early candidate for some kind of new FDA expedited process.

The potential societal and fiscal benefits of a successful treatment will likely bring pressure on the FDA to act.

Alzheimer’s is a major drain on Medicare, Medicaid, and Social Security Disability budgets. A successful treatment will change the math on all of those programs.